Traws Pharma (NASDAQ:TRAW) Trading 8.8% Higher – Here’s What Happened

Traws Pharma, Inc. (NASDAQ:TRAW) traded up 8.8% on Monday . The company traded as high as $1.64 and last traded at $1.61. 21,635 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 54,220 shares. The stock had previously closed at $1.48.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Traws Pharma in a research note on Monday, December 22nd. LADENBURG THALM/SH SH raised Traws Pharma to a “strong-buy” rating in a research note on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Traws Pharma Price Performance

The stock has a 50 day moving average price of $1.80 and a two-hundred day moving average price of $2.01. The firm has a market capitalization of $9.94 million, a price-to-earnings ratio of 0.01 and a beta of 1.61.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp acquired a new position in Traws Pharma during the 4th quarter worth $29,000. Two Sigma Investments LP grew its stake in Traws Pharma by 37.1% during the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after purchasing an additional 5,955 shares in the last quarter. XTX Topco Ltd grew its stake in Traws Pharma by 294.2% during the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after purchasing an additional 31,502 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in Traws Pharma during the 4th quarter worth $56,000. Finally, Geode Capital Management LLC grew its stake in Traws Pharma by 41.9% during the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after purchasing an additional 18,213 shares in the last quarter. 7.95% of the stock is owned by institutional investors and hedge funds.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.